Syndax Pharmaceuticals, Inc. (SNDX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
SNDX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
SNDX Revenue Analysis (2013–2024)
As of February 28, 2026, Syndax Pharmaceuticals, Inc. (SNDX) generated trailing twelve-month (TTM) revenue of $111.6 million, reflecting explosive growth of +267.0% year-over-year. The most recent quarter (Q3 2025) recorded $45.9 million in revenue, up 20.8% sequentially.
Looking at the longer-term picture, SNDX's 5-year compound annual growth rate (CAGR) stands at +73.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $139.7 million in 2021.
Revenue diversification analysis shows SNDX's business is primarily driven by Milestone Revenue (68%), and Net Product Revenues (32%). With over half of revenue concentrated in Milestone Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY), SNDX has underperformed the peer group in terms of revenue growth. Compare SNDX vs INCY →
Peer Comparison
Compare SNDX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SNDXCurrent | $112M | +267.0% | +73.3% | -1434.4% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $23.7M | - | $22.9M | 96.5% | $-339,672,000 | -1434.4% |
| 2023 | $0 | - | $0 | - | $-229,954,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $-151,757,000 | - |
| 2021 | $139.7M | +9109.6% | $139.7M | 100.0% | $26.2M | 18.8% |
| 2020 | $1.5M | +0.0% | $1.5M | 100.0% | $-71,423,000 | -4708.2% |
| 2019 | $1.5M | +0.0% | $1.5M | 100.0% | $-57,539,000 | -3792.9% |
| 2018 | $1.5M | -28.0% | $1.5M | 100.0% | $-75,876,000 | -5001.7% |
| 2017 | $2.1M | +72.8% | $2.1M | 100.0% | $-61,954,000 | -2939.0% |
| 2016 | $1.2M | +94.6% | $1.2M | 100.0% | $-43,766,000 | -3587.4% |
| 2015 | $627K | - | $627K | 100.0% | $-20,513,000 | -3271.6% |
See SNDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNDX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SNDX vs AGIO
See how SNDX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SNDX's revenue growth accelerating or slowing?
SNDX revenue is accelerating at +267.0% year-over-year, exceeding the 5-year CAGR of +73.3%. TTM revenue reached $112M. Growth momentum has increased versus prior periods.
What is SNDX's long-term revenue growth rate?
Syndax Pharmaceuticals, Inc.'s 5-year revenue CAGR of +73.3% reflects the sustained expansion pattern. Current YoY growth of +267.0% is above this long-term average.
How is SNDX's revenue distributed by segment?
SNDX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.